Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 23

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 23
---

    the
    timing and cost of, and level of investment in, research and development activities relating to our clinical assets, which may change
    from time to time;

    ●
    the
    cost of manufacturing our clinical assets, which may vary depending on FDA guidelines and requirements, and the quantity of production;

    ●
    our
    ability to obtain additional funding to develop our clinical assets;

    ●
    expenditures
    that we will or may incur to acquire or develop additional clinical assets and technologies;

    ●
    the
    level of demand for our clinical assets, should they receive approval, which may vary significantly;

43

    ●
    potential
    side effects of our clinical assets that could delay or prevent commercialization or cause an approved drug to be taken off the market;

    ●
    the
    ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our clinical assets, if approved;

    ●
    our
    dependency on third-party manufacturers to supply or manufacture our clinical assets;

    ●
    our
    ability to establish an effective sales, marketing, and distribution infrastructure in a timely manner;

    ●
    market
    acceptance of our clinical assets, if approved, and our ability to forecast demand for those clinical assets;

    ●
    our
    ability to receive approval and commercialize our clinical assets outside of the U.S.;

    ●
    our
    ability to establish and maintain collaborations, licensing, or other arrangements;

    ●
    our
    ability and third parties’ abilities to protect intellectual property rights;

    ●
    costs
    related to and outcomes of potential litigation or other disputes;

    ●
    our
    ability to adequately support future growth;

    ●
    our
    ability to attract and retain key personnel to manage our business effectively;

    ●
    potential
    liabilities associated with hazardous materials;

    ●
    our
    ability to maintain adequate insurance policies; and

    ●
    future
    accounting pronouncements or changes in our accounting policies.

44

Fluctuations
in foreign currency could have an effect on our reported results of operations.

Our
exposure to fluctuations in foreign currency rates results primarily from the translation exposure associated with the preparation of
our consolidated financial statements, as well as from transaction exposure associated with transactions in currencies other than our
functional currency. While our consolidated financial statements are reported in U.S. dollars, our financial statements of foreign subsidiaries
are